Heat Biologics Announces Proposed Public Offering of Common Stock

Mar 22, 2017

Heat Biologics Reports Positive Interim Phase 2 Lung Cancer Results in Patients Treated with HS-110 in Combination with a Checkpoint Inhibitor

Mar 21, 2017

Heat Biologics, Inc. to Present at The MicroCap Conference on April 4th in New York City

Mar 20, 2017

Florida Department of Health Awards Three-Year Grant to Develop gp96-based Zika Vaccine

Mar 16, 2017

Heat Biologics Meets Efficacy Endpoint in its Phase 1b Lung Cancer Trial to Progress to Phase 2

Mar 13, 2017

Heat Biologics to Present at 29th Annual ROTH Conference

Mar 9, 2017

Heat Biologics Announces Agreement to Acquire Pelican Therapeutics

Mar 8, 2017

Heat Biologics to Present at the American Association for Cancer Research (AACR) Annual Meeting

Mar 2, 2017

Heat Biologics Presents Immune Data on its HS-410 Phase 2 Bladder Cancer Trial at the Genitourinary Cancers Symposium

Feb 17, 2017

Heat Biologics to Present at the Genitourinary Cancers Symposium

Feb 14, 2017